

## FURTHER ACKNOWLEDGMENTS FOR SUCROSOMIAL IRON®

**Pisa, 5 November 2018** – Further acknowledgments among the scientific community of the value of Sucrosomial Technology®, the patent that has allowed PharmaNutra Group to gain a leadership position in the production of iron-based nutritional supplements .

Following the complete studies published at the beginning of October ([www.pharmanutra.it/en/news/nuovi-riconoscimenti-ferro-sucrosomiale/](http://www.pharmanutra.it/en/news/nuovi-riconoscimenti-ferro-sucrosomiale/)) in the International Journal of Molecular Sciences and in Nutrients, thanks to the cooperation between the **Scientific Direction of PharmaNutra** and **important Italian universities**, these two new publications offer further confirmation of the value of Sucrosomial Iron®.

The first study - **"Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial® iron supplementation: a quality improvement assessment study"**, published in International Orthopaedics - features a detailed scientific examination of the use of SiderAL® in orthopaedics, and its correlation with quicker and more effective post-operative recovery. In this important study on PBM in orthopaedics, conducted on 300 patients, **Professor Marco Scardino, an anaesthetist of the Hip and Prosthetics Orthopaedic Unit of the Humanitas Scientific Institute for Research and Healthcare in Rozzano (Milan)**, showed that in the group of patients who were administered SiderAL® Forte during the pre-operative period, there was a smaller drop in haemoglobin levels during the post-operative stage, as well as shorter stays in hospital, fewer transfusions and a final saving of € 1763.25 per patient. [Download the full text.](#)

The second publication, which appeared in the magazine Pharmaceuticals and was entitled **"Sucrosomial® Iron: a new generation iron for improving oral supplementation"**, took the form of a review that for the first time brought together most of the evidence obtained in recent years on the absorption and efficacy of sucrosomial iron. It also provided concrete results regarding the greater tolerability of Sucrosomial® Iron compared to other types of iron, highlighting, among other points, that it is essential to deal with and manage iron deficiency, also with a view to preventing actual anaemia and the numerous consequences it brings with it.

Based on this proposition, the review shows the results of using Sucrosomial® Iron as a supplement in patients suffering from iron deficiency with different causes. In all contexts, it emerges that the innovative composition of Sucrosomial® Iron allows for improved bioavailability of the mineral, together with reduced gastrointestinal compliance compared to traditional mineral salts. [Download the full text.](#)

This review published by Prof. Manuel Muñoz, a renowned expert in transfusion medicine, haematology and iron metabolism, establishes an important benchmark, describing the unique characteristics of sucrosomial iron and acknowledging its value, thanks to a body of scientific evidence collected over a number of years.

**Germano Tarantino, Scientific Director of PharmaNutra, commented:** "The studies recently published show that Sucrosomial® Iron can be considered the first-choice oral iron supplement solution in cases of iron deficiency or an increased iron requirement, for the wellbeing of all those who require a nutritional intake of iron. At the same time, they demonstrate that PharmaNutra's research to develop sucrosomial technology is continuing to confirm the unique, innovative nature of the company's patents".

\*\*\*

### PharmaNutra S.p.A.

Founded and guided by President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003 that develops unique nutraceutical supplements and innovative nutritional devices, taking care of the entire production process, from the proprietary raw materials to the finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 79 of them published with more than 5000 patients treated. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 180 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 70 countries abroad, through 35 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence. <http://www.PharmaNutra.it>

### For Information:

#### PharmaNutra S.p.A.

Via Delle Lenze, 216/b  
56122 Pisa  
Tel. +39 050 7846500  
Fax +39 050 7846524  
[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

#### Nomad & Specialist

**CFO SIM S.p.A.**  
Via dell'Annunciata 23/4  
20121 Milan  
Tel. +39 02 303431  
[ecm@cfosim.com](mailto:ecm@cfosim.com)

#### Press Office

#### Spriano Communication&Partners

Tel. +39 02 83635708  
Matteo Russo - Cristina Tronconi  
Mob. +39 347 9834881 +39 346 0477901  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)